Introduction: Prolactinomas are pituitary tumors with a very low prevalence in childhood and adolescence compared to adulthood. This condition is preferentially treated with dopamine agonists. Resistance to these drugs is rare. Case Report: We describe the case of a boy diagnosed with macroadenoma at the age of 9 and followed up for 21 years. He did not fully respond to treatment with dopamine agonists. His initial prolactin level was 2,400 ng/mL (in males, normal values are <16.0 ng/mL) and never normalized. At the last assessment, his prolactin level was 21.5 ng/mL, recorded after 21 years of treatment with the dopamine agonist cabergoline at a dose as high as 4.5 mg per week. Although the prolactin level remained elevated throughout the follow-up period, the patient never presented a low testosterone level and had normal pubertal development. An MRI of the sella turcica showed that the tumor became progressively cystic and disappeared, but a normal pituitary gland was observed. The pituitary gland retained its normal functions despite a partially empty sella. Discussion: Long-term treatment with high doses of cabergoline may cause cystic degeneration of a prolactinoma considered to be resistant to this treatment, but we cannot rule out the possibility that this outcome represents the natural development of the tumor.

Keywords:
Prolactinoma, Childhood, Dopamine agonists, Resistance, Treatment
1.
Glezer A, Bronstein MD: Prolactinoma. Arq Bras Endocrinol Metab 2014; 58: 118–123.
2.
Vilar L, Fleseriu M, Bronstein MD: Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metab 2014; 58: 9–22.
3.
Casulari LA, Motta LDC: Dogmas da prolactina: a necessidade de rever conceitos. Bras Med 2014; 51: 248–259.
4.
Daly AF, Vanbellinghen JF, Khoo SK, et al: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007; 92: 1891–1896.
5.
Raappana A, Koivukangas J, Ebeling T, Pirila T: Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 2010; 95: 4268–4275.
6.
Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485–534.
7.
Harrington MH, Casella SJ: Pituitary tumors in childhood. Curr Opin Endocrinol Diabetes Obes 2012; 19: 63–67.
8.
Steele CA, MacFarlane IA, Blair J, Cuthbertson DJ, Didi M, Mallucci C, Javadpour M, Daousi C: Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol 2010; 163: 515–522.
9.
Ciccarelli A, Daly AF, Beckers A: The epidemiology of prolactinomas. Pituitary 2005; 8: 3–6.
10.
Mindermann T, Wilson CB: Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41: 359–368.
11.
Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenicky P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon PF, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P: Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 2015; 100: 1177–1186.
12.
Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998; 83: 2777–2780.
13.
Eren E, Yapici S, Cakir ED, Ceylan LA, Saglam H, Tarim O: Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011; 3: 65–69.
14.
Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A: Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000; 13: 261–267.
15.
Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P: Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577–584.
16.
Kovacs K, Stefaneanu L, Hovarth E: Prolactin producing pituitary tumour: resistance to dopamine agonist therapy. J Neurosurg 1995; 82: 886–890.
17.
Araújo J, Gomes BS, Vilar L: Investigação da criança com baixa estatura; in Vilar L (ed): Endocrinologia Clínica, ed 5. Rio de Janeiro, Guanabara Koogan, 2013, pp 191–212.
18.
Howlett TA, Wass JÁ, Grossman A, Plowman PN, Charlesworth M, Touzel R, Rees LH, Savage MO, Besser GM: Prolactinomas presenting as primary amenorrhea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol (Oxf) 1989; 30: 131–140.
19.
Kane LA, Leinung MC, Sheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D: Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994; 79: 1135–1140.
20.
Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon OS, Shah NS: Clinical profile and long term follow up of children and adolescents. Pituitary 2009; 12: 186–189.
21.
Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P: Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 2010; 73: 187–192.
22.
Fideleff HL, Boquette HR, Suarez MG, Azaretzky M: Prolactinoma in children and adolescents. Horm Res 2009; 72: 197–205.
23.
Vroonen L, Jaffrain-Rea M-L, Petrossians P, et al: Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 2012; 167: 651–662.
24.
Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, Barros AI, Fa-ria M, Nascimento GC, Lima JG, Nóbrega LH, Cruz TP, Mota A, Ramos A, Violante A, Lamounier Filho A, Gadelha MR, Czepielewski MA, Glezer A, Bronstein MD: Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1,234 patients. J Endocrinol Invest 2008; 31: 436–444.
25.
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500–509.
26.
Molitch ME: Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43–52.
27.
Delgrange E, Daems T, Verhelst J, Abs R, Maiter D: Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009; 160: 747–752.
28.
Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001; 86: 5256–5261.
29.
Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876–883.
30.
Passos VQ, Souza JFS, Musolino NRC, Bronstein MD: Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 2002; 87: 3578–3582.
31.
Gan H-W, Bulwer C, Jeelani O, Levine MA, Korbonits M, Spoudeas HA: Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. Int J Pediatr Endocrinol 2015; 2015: 15.
32.
Morris AH, Harrington MH, Churchill DL, Olshan JS: Growth hormone stimulation testing with oral clonidine; 90 min is the preferred duration for the assessment of growth hormone reserve. J Pedriatr Endocrinol Metab 2001; 14: 1657–1660.
33.
Papadia C, Naves LA, Motta LDC, Barbosa Filho RF, Suzuki MTM, Casulari LA: Growth hormone provocation tests and their prediction in the growth of children treated for acute lymphoblastic leukemia. Minerva Endocrinol 2006; 31: 211–218.
34.
Sklar C, Mertens A, Walter A, Mitchel D, Nesbit M, O’Leary M, Hutchinson R, Meadows A, Robison L: Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1,800 and 2,400 centigrays of cranial irradiation. J Pediatr 1993; 123: 59–64.
35.
Darendeliler F, Spinu I, Bas F, Bundak R, Isgüven P, Arslanoglu I, Saka N, Sükür M, Günöz H: Reevaluation of growth hormone deficiency during and after growth hormone (GH) treatment: diagnostic value of GH tests and IGF-1 and IGFBP-3 measurements. J Pediatr Endocrinol Metab 2004; 17: 1007–1012.
36.
Molitch ME: Management of the pregnant patient with prolactinoma. Eur J Endocrinol 2015; 172:R205–R213.
37.
Vilar L, Naves LA, Freitas MC, Moura E, Ca-nadas V, Campos R, Albuquerque JL, Lyra R, Casulari LA: Clinical and laboratorial features greatly overlap in patients with macroprolactinemia and monomeric hyperprolactinemia. Minerva Endocrinol 2007; 32: 79–86.
38.
Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP: Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 2015; 18: 820–830.
39.
Dyer EH, Civit T, Visot A, Decalande O, Derome P: Transesphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994; 34: 207–212.
40.
De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N: Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest 2001; 24: 92–97.
41.
Pandey P, Ojha BK, Mahapatna AK: Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci 2005; 12: 124–127.
S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.